Guizhou Sanli Pharmaceutical Co (603439) Fair Value & Analysis

Healthcare · CN · Market cap 6.1B CNY

Analysis

Guizhou Sanli Pharmaceutical Co (603439) currently trades at ¥15.43, while our model-based Fair Value estimate is ¥5.56 — implying the stock looks roughly 64.0% overvalued today. We read business quality at 92/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Guizhou Sanli Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the plantation, research, development, production, and sale of pharmaceutical products in China. The company offers respiratory system, tonic, gynecological, and orthopedic medications, as well as cardiovascular and cerebrovascular drugs, and other medicines. It also provides products in various dosage forms, including sprays, granules, capsules, pills, tablets, medicated wines, and ointments. The company was founded in 1995 and is based in Anshun, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.